Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 3, 2000, Pages 727-731

  Nomeir, Amin A ^a   Kumari, Pramila ^a   Hilbert, Mary Jane ^a   Gupta, Samir ^a   Loebenberg, David ^a   Cacciapuoti, Anthony ^a   Hare, Roberta ^a   Miller, George H ^a   Lin, Chin Chung ^a   Cayen, Mitchell N ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ANTIFUNGAL AGENT; METHYLCELLULOSE; POSACONAZOLE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG RESEARCH; FOOD DRUG INTERACTION; MALE; MINIMUM INHIBITORY CONCENTRATION; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT;

ANIMALS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FOOD-DRUG INTERACTIONS; MACACA FASCICULARIS; MALE; MICE; RABBITS; RATS; TRIAZOLES;

EID: 0033998522     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.3.727-731.2000     Document Type: Article

References (14)

1. Armstrong, D. 1989. Problems in management of opportunistic fungal infections. Rev. Infect. Dis. 11:S1591.
2. Emmons, C. W. 1977. Medical mycology, 3rd. ed. Lea and Febiger, Philadelphia, Pa.
3. Gilbaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed., p. 409-417. Marcel Dekker, New York, N.Y.
4. Hebbard, G. S., M. W. Sun, F. Bochner, and M. Horowitz. 1995. Pharmacokinetic considerations in gastrointestinal motor disorders. Clin. Pharmacokinet. 28:41-66.
5. Lutz, J. E., K. V. Clemons, B. H. Aristizabal, and D. A. Stevens. 1997. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob. Agents Chemother. 41:1558-1561.
6. Nomeir, A. A., P. Mojavarian, T. Kosoglou, M. B. Affrime, J. Nezamis, E. Radwanski, C. C. Lin, and M. N. Cayen. 1996. Influence of food on the oral bioavailability of loratadine and pseudoephedrine from extended-release tablets in healthy volunteers. J. Clin. Pharm. 36:923-930.
7. Oakley, K. L., G. Morrissey, and D. W. Denning. 1997. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob. Agents Chemother. 41:1504-1507.
8. Oakley, K. L., C. B. Moore, and D. W. Denning. 1997. In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob. Agents Chemother. 41:1124-1126.
9. Perfect, J. R., G. M. Cox, R. K. Dodge, and W. A. Schell. 1996. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob. Agents Chemother. 40:1910-1913.
10. Pfaller, M. A., S. Messer, and R. N. Jones. 1997. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 41:233-235.
11. Sugar, A. M., and X.-P. Liu. 1996. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob. Agents Chemother. 40:1314-1316.
12. Walsh, T. J., and P. A. Pizzo. 1988. Nosocomial fungal infections: a classification for hospital-acquired infections and mycoses arising from endogenous flora and reactivation. Annu. Rev. Microbiol. 42:517.
13. Welling, P. G. 1986. Pharmacokinetics: process and mathematics. American Chemical Society, Washington, D.C.
14. Welling, P. G. 1977. Influence of food and diet on gastrointestinal drug absorption: a review. J. Pharmacokinet. Biopharm. 5:291-334.